Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.86 -0.13 (-0.27%)

Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

96 97 Next >

Novo Nordisk (NYSE:NVO) Embodies Quality Investing Principles ↗

December 06, 2025

Novo Nordisk exemplifies quality investing with exceptional profitability, strong growth, and a durable competitive advantage in healthcare.

Via Chartmill

Do These 3 Healthcare Stocks Need a Checkup? ↗

December 05, 2025

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Via The Motley Fool

Topics Intellectual Property

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗

December 05, 2025

The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.

Via The Motley Fool

Trump Administration Eases Investment Deadlines For Large Pharma Companies: Report ↗

December 04, 2025

The report added that at least one of these companies expects to fulfill the multi-billion-dollar investment pledge in full by Jan. 1, 2029.

Via Stocktwits

Topics Artificial Intelligence Government Workforce

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study ↗

November 25, 2025

Via Stocktwits

Novo Nordisk Stock Tumbles: HSBC Downgrades After ‘Lottery Ticket’ Alzheimer’s Bet Fails, But Retail Traders Call Selloff ‘Ridiculous’ ↗

November 24, 2025

Via Stocktwits

1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year ↗

December 03, 2025

A key catalyst may be right around the corner.

Via The Motley Fool

Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock? ↗

December 03, 2025

There is more to this news than meets the eye.

Via The Motley Fool

Topics Economy Government

Novo Nordisk Defends Semaglutide Alzheimer’s Trials After Studies Miss Goals ↗

December 02, 2025

A Novo Nordisk executive outlined the scientific rationale behind testing Semaglutide in Alzheimer’s disease at a meeting on Tuesday.

Via Stocktwits

The Shifting Tides: How Retail and Institutional Forces Reshape Market Dynamics

December 02, 2025

As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across...

Via TokenRing AI

Topics Artificial Intelligence Economy Emissions

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗

December 01, 2025

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.

Via Stocktwits

Topics Intellectual Property

Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy ↗

December 01, 2025

Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect.

Via Stocktwits

Topics Economy Government

Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. ↗

December 01, 2025

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?

Via The Motley Fool

This 7% Yielder Could Be a Top AI Play ↗

November 30, 2025

One drug developer could be on the cusp of AI-powered glory.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Why Novo Nordisk Stock Just Hit a 4-Year Low ↗

November 29, 2025

Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

Via The Motley Fool

Novo Nordisk A/S (NYSE:NVO) Offers a Strong Dividend and Sound Fundamentals ↗

November 29, 2025

Novo Nordisk (NVO) is a top dividend stock with a 3.71% yield, strong earnings, and a history of reliable dividend growth, offering dependable income.

Via Chartmill

Novo Nordisk Stock Investors Get Huge News on Drug Trial Results ↗

November 28, 2025

Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments.

Via The Motley Fool

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Via The Motley Fool

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Via Stocktwits

Topics ETFs

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Why Novo Nordisk Stock Is Moving Higher Today ↗

November 26, 2025

Patients could soon access higher-dose injections.

Via The Motley Fool

Topics Stocks

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗

November 26, 2025

The weight loss drug market may approach almost $100 billion by the end of the decade.

Via The Motley Fool

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

Here's Why Novo Nordisk Stock Popped Today ↗

November 25, 2025

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Via The Motley Fool

Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors ↗

November 25, 2025

Discover Novo Nordisk (NVO), a potentially undervalued stock with strong profitability, solid financial health, and a good dividend yield.

Via Chartmill

Why Novo Nordisk Stock Sank 5.6% Today ↗

November 24, 2025

Semaglutide was no better than a placebo.

Via The Motley Fool

Topics Stocks

Hims, Block, and NRG Just Launched Huge Stock Buybacks ↗

November 24, 2025

Via MarketBeat

Biggest Stock Movers Today, Nov. 24: AVGO, NVO, & More ↗

November 24, 2025

Stocks were up sharply to start the holiday week.

Via The Motley Fool

Topics Artificial Intelligence Government Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

96 97 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.